Menu
Washingtoner
  • Home
  • Health
  • Artificial Intelligence
  • Technology
  • Entertainment
  • Software
  • Business
  • Education
  • Real Estate
Washingtoner

Global Myeloproliferative Neoplasm Drugs Market to Surpass US$ 10,966.8 Million by 2027, Says Coherent Market Insights (CMI)
Washingtoner/10101104

Trending...
  • Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
  • Iglesia.com Positioned in Multimillion-Dollar Domain Market with $10 Million Asking Price
  • ViewDNS.info Launches Monitors, Alerting Teams the Moment Something Changes on Their Domains
SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global myeloproliferative neoplasm drugs market is estimated to be valued at US$ 8,379.5 million in 2020 and is expected to exhibit a CAGR of 3.9% over the forecast period (2020-2027).

Key Trends and Analysis:

The increasing incidence of myeloproliferative neoplasm is expected to drive growth of the global myeloproliferative neoplasm drugs market over the forecast period. According to the National Organization for Rare Disorders (NORD) 2020, men are more likely to be affected than women with polycythemia vera and this disorder is expected to affect around two people per 100,000 in the general population globally.

Moreover, the increasing number of pipeline products for the treatment of myeloproliferative neoplasm is expected to fuel growth of the global myeloproliferative neoplasm drugs market in the near future. For instance, on January 7, 2021, PharmaEssentia Corporation, a company focusing on research and development in biopharmaceutical industry, announced the initiation of investigational study phase 3 pivotal clinical trial of SURPASS ET, [Ropeginterferon Alfa-2b (P1101)]. SURPASS ET is a novel mono-pegylated proline interferon under evaluation for the treatment of the essential thrombocythemia (ET) type of myeloproliferative neoplasm (MPNs).

Among regions, North America is expected to register highest growth rate, owing to increasing number of pipeline products for the treatment of myeloproliferative neoplasm. For instance, in December 2020, AbbVie Inc. announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial, evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA/VENCLYXTO (venetoclax) in previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), during an oral presentation session at the virtual 2020 American Society of Hematology (ASH) Annual Meeting.

More on Washingtoner
  • LGF Lab Gas Flow Launches Fully Automatic Laboratory Gas Changeover Manifold System with Ultra High Purity Gas Regulator Valve
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • Inaugural 12 Trees of Christmas gala raises $525,000 for DMG research and family support
  • BitTitan Expands MigrationWiz with SharePoint Sites Migration and Simplified Collaboration Licensing
  • Olympic champion Katie Moon to compete at Pole Vault in Paradise in Key West

Request Sample Copy of this Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/930

Key Market Takeaways:


The global myeloproliferative neoplasm drugs market is expected to exhibit a CAGR of 3.9% over the forecast period, as key players are focusing on strategies such as mergers and acquisitions in order to strengthen their position in the market. For Instance, in February 2020, F. Hoffmann-La Roche AG completely acquired Promedior, Inc., a clinical stage biotechnology company. As a result of this acquisition, F. Hoffmann-La Roche AG would obtain full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, including PRM-151.

Competitive Landscape:

Key players operating in the global myeloproliferative neoplasm drugs market include Novartis International AG, PharmaEssentia Corporation, Bristol - Myers Squibb, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Incyte, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Gamida Cell, Sierra Oncology, Inc., CTI BioPharma Corp., Imago BioSciences, AbbVie Inc., and Constellation Pharmaceuticals

Buy-Now this Research Report for detailed market insights @
https://www.coherentmarketinsights.com/insight/buy-now/930

Market Segmentation:
  • Global Myeloproliferative Neoplasm Drugs Market, By Drug Class:
    • Demethylation Agents
    • Tyrosine kinase Inhibitor
    • Multikinase Inhibitors
    • JAK2 Inhibitor
    • Others
  • Global Myeloproliferative Neoplasm Drugs Market, By Indication:
    • Ph+ Chronic myelogenous leukemia (CML)
    • Ph- Myeloproliferative Neoplasms (MPNs)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
      • Essential thrombocythemia (ET)
  • Global Myeloproliferative Neoplasm Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Myeloproliferative Neoplasm Drugs Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country/Region:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa

Related Market Intelligence Reports:

More on Washingtoner
  • Smith Strong Merges With Gravis Law, Bringing Gravis Law to Virginia
  • Turkish Engineer Who Cracked Wall Street's Algorithm Launches Hermes AI Analyzer
  • UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
  • The Great Junk Hunt Returns to Puyallup: The Ultimate Holiday Vintage Market is Back!
  • Green Revolution CBD Spotlights Its Water-Soluble Focus Tincture With CBD, CBG and Lion's Mane

Urinary Incontinence Treatment Drugs Market, by Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, and Other Type), by Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Read-more: https://www.coherentmarketinsights.com/market-insight/urinary-incontinence-treatment-drugs-market-4400

About Us:

Coherent Market Insights
is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • City of Tacoma Awarded $2.25 Million in Federal Highway Safety Improvement Program Grant Funding for South 21st Street Corridor
  • New Self-Service Sandbag Station at Tacoma Recovery and Transfer Center
  • Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
  • Business News & Info Goes Inside Paragon FX Group's Hunt for Original Film Props
  • Kitchen Table Economics: An Invitation to Think Differently
  • Win a $5,000 VIP Family Experience at the 100th Thanksgiving Day Parade in New York City
  • CB Stuffer Announces Private Sale to Secure Future of Brand Growth
  • The Fifth Annual "Bamboo Lantern Festival" to Illuminate Tokyo Mizumachi and Sumida River Walk®
  • Iglesia.com Positioned in Multimillion-Dollar Domain Market with $10 Million Asking Price
  • Searching for the Next LBE Creator: CalArts Launches First-Ever D.R.E.A.M.S. Pitch Competition
  • TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
  • Spokane: Gesa Pavilion Concert Series Welcomes New Concert Promoter
  • Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
  • Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
  • ViewDNS.info Launches Monitors, Alerting Teams the Moment Something Changes on Their Domains
  • Kindering's 21st Luncheon Raises $220,000+ to Support Children with Disabilities and Their Families
  • Philadelphia-Area Entrepreneur Nouho M Kanneh Builds $37 Million Net Worth Across Real Estate, E-Commerce and Retail
  • Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
  • The World's No.1 Superstar® Brings Christmas Back in Grand Style with Music, Cinematic Glamour, and Luxury Fashion
  • New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)
_catLbl0 _catLbl1

Popular on Washingtoner

  • Pre-Seed VC Martin Tobias Makes Fundraising Tool Available to Every Startup CEO as Investor Match - 317
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX) - 275
  • LocalsVoted Launches: Local Rankings From Phone-Verified Votes, Not Paid Placement - 173
  • Simpalm Staffing Launches Tax Preparer Staffing for U.S. CPA Firms - 142
  • Sycamore Dove Releases "Loving Every Moment" - 117
  • One in three Americans may have lost track of retirement savings from a previous job - 113
  • Datavalet Named One of Quebec's Best Workplaces™ for 2026 - 107
  • Tacoma: OMWBE Active Certification Class on November 16
  • Nextlink Internet Deploys netElastic to Modernize Its Hybrid Broadband Network
  • ThriveStack citedby launches Prompt Research to find the prompts buyers ask in AI search

Similar on Washingtoner

  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • Security Planning Tips For Your Holiday Event From Access Patrol Services
  • Kitchen Table Economics: An Invitation to Think Differently
  • Iglesia.com Positioned in Multimillion-Dollar Domain Market with $10 Million Asking Price
  • TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
  • Searching for the Next LBE Creator: CalArts Launches First-Ever D.R.E.A.M.S. Pitch Competition
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute